Clinical trials
Observational trials in Cyprus
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Recruiting | 11 |
| Unknown status | 7 |
| Not yet recruiting | 6 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eastern Mediterranean University | 8 |
| University of Cyprus | 4 |
| Utku Gürhan | 3 |
| Bozok University | 2 |
| Ceren Melahat Donmezer | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| European Society of Cardiology | 2 |
| Nicosia General Hospital | 2 |
| Pfizer | 2 |
| Akcea Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 3 |
| Pain | 3 |
| Amyloidosis | 2 |
| Brain Injuries, Traumatic | 2 |
| COVID-19 | 2 |
| Cerebral Palsy | 2 |
| Charcot-Marie-Tooth Disease | 2 |
| Heart Failure | 2 |
| Hereditary Sensory and Motor Neuropathy | 2 |
| Hypersensitivity | 2 |
Trials
Showing 51 to 65 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.